Results 61 to 70 of about 5,690 (176)
Zhongguo Linchuang YixueObjectiveTo investigate predictive value of soluble growth stimulation-expressed gene 2 protein (sST2), cardiac troponin T (cTnT), and creatine kinase-myocardial band (CK-MB) for steroid resistance and prognosis in patients with immune checkpoint ...
Yinman Wang +5 more
doaj +1 more source
Beyond Traditional Screening: The Future of Heart Failure Detection With Biomarkers and AI
iNew Medicine, Volume 2, Issue 3, September 2026.Advancing HF Screening: Integrating Technology and Risk Factors Across Eras. This diagram provides a comprehensive review of the historical developments and projected trends of heart failure (HF) screening methodologies, with the prevalent risk factors for HF depicted at the base.
Xiaofeng Fang +9 more
wiley +1 more source
Scientific ReportsSoluble ST2 (sST2) is released in response to vascular congestion, inflammation, and pro-fibrotic stimuli. In heart failure (HF), elevated levels of sST2 are associated with a higher risk of adverse clinical outcomes.
Elena Revuelta-López +7 more
doaj +1 more source
Update on biologic and small molecules treatments in pediatric allergic diseases
Pediatric Allergy and Immunology, Volume 37, Issue 9, September 2026.This graphical abstract summarizes key targets, mechanisms of action, and indications of biologic and small molecules treatments in pediatric allergic diseases.abbreviations : BAS, basophil; BTK, Bruton tyrosine kinase; cDC, conventional dendritic cell; IgE, immunoglobulin E; FCER1, high affinity IgE receptor; IL, interleukin; IL4R, IL4 receptor; JAK ...
Herman T. den Dekker +10 more
wiley +1 more source
The Effects of Replacing Sst2 with the Heterologous RGS4 on Polarization and Mating in Yeast [PDF]
Biophysical Journal, 2010 RGS proteins stimulate the deactivation of heterotrimeric G-proteins. The yeast RGS protein Sst2 is regulated at both the transcriptional and posttranscriptional levels. We replaced the SST2 gene with the distantly related human RGS4 gene, which consists of the catalytic domain and an N-terminal membrane attachment peptide, and replaced the native ...
Tanaka, Hiromasa, Yi, Tau-Mu
openaire +2 more sources
Journal of Clinical Laboratory Analysis, Volume 40, Issue 15, August 2026.Allogeneic hematopoietic stem cell transplantation remains a potentially curative therapy for many hematological malignancies; however, its success is significantly limited by acute graft‐versus‐host disease (aGVHD), a leading cause of post‐transplant morbidity and mortality in which endothelial dysfunction plays a central role.
Katarina Klinar, Helena Podgornik
wiley +1 more source
Antibody–Drug Conjugates and Peptide–Drug Conjugates: Current Understandings and Future Perspectives
MedComm, Volume 7, Issue 8, August 2026.The graphic summarizes the design principles, intracellular trafficking, clinical progress, challenges, and future directions of antibody–drug conjugates (ADCs) and peptide–drug conjugates (PDCs). ADCs consist of a tumor‐targeting antibody, a chemical linker, and a potent payload, whereas PDCs use peptide ligands to deliver cytotoxic, radionuclide, or ...
Ruxi Zheng +9 more
wiley +1 more source
Acute Myocarditis: From Pathophysiology to Risk‐Stratified Management—A Clinical Review
European Journal of Clinical Investigation, Volume 56, Issue 8, August 2026.Stepwise approach to patients with suspected acute myocarditis, integrating the 2024 American College of Cardiology (ACC) four‐stage classification (Stages A–D) and the 2025 European Society of Cardiology (ESC) inflammatory myopericardial syndrome (IMPS) framework. Step 1 (Initial Assessment): clinical presentation, first‐line investigations (ECG, high‐
Michele Golino +9 more
wiley +1 more source
BMC Cardiovascular DisordersAim The objective of this study was to investigate the level of soluble suppression of tumorigenicity-2 (sST2) in patients with acute ST-segment elevation myocardial infarction (STEMI) following primary percutaneous coronary intervention (PCI), and to ...
Shan Huang +3 more
doaj +1 more source
Clinical Pharmacology in Drug Development, Volume 15, Issue 7, July 2026.Abstract Paltusotine is a novel, nonpeptide, once‐daily oral, selective somatostatin 2 receptor (SST2) agonist. We evaluated the pharmacokinetics, pharmacodynamics, and safety of oral paltusotine in healthy Japanese adults in single‑dose (20, 40, 60, 80 mg) and repeated‑dose (40 mg once daily for 7 days in a two‐sequence, two‑period crossover design ...
Fumio Otsuka +7 more
wiley +1 more source